Braeburn's Buprenorphine Candidate Faces Safety Gauntlet At US FDA Panel
Executive Summary
Unlike its potential competitor Indivior, Braeburn didn't submit a proposed REMS for its subcutaneous opioid abuse treatment, but if approved, both buprenorphine candidates will probably end up with similar risk management restrictions.
You may also be interested in...
Braeburn's Buprenorphine Bid: Eight Dosing Options Part Of "All Hands On Deck" Approach
With an FDA decision on its buprenorphine injection expected by Jan. 19, Scrip spoke with Braeburn executives at J.P. Morgan about the company's justification for four once-weekly and four once-monthly doses, competition in the opioid use disorder (OUD) market and the need for more OUD therapies.
Braeburn's Buprenorphine Clears Advisory Committee, But US FDA Likely To Limit Dosage
Seventeen of the panelists voted that the clinical data support approval for some of Braeburns proposed doses, but no one supported the highest proposed monthly dose.
Buprenorphine Injectable Opioid Abuse Treatment: Will REMS Prevent Misuse?
US FDA worries Indivior's formulation in prefilled syringes could lead to adverse events if patients obtain direct access; advisory committee to consider if REMS requiring administration by healthcare providers is adequate.